Rosiglitazone Versus Placebo in Chronic Stable Angina

• Status: Terminated
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

We wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes, could be used as a new treatment for angina when compared with placebo in overweight subjects who do not have overt diabetes. The drug will be given for 3 months and the subjects will be have their angina tested, by way of exercise testing, angina quality of life questionnaire and 24-hour ECG monitoring before and after using the drug.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Glasgow
• Collaborators: British Heart Foundation; GlaxoSmithKline
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Chronic stable angina - to see if this improves

• Previous positive exercise tolerance test - to ensure that repeating it yields a result

• Disease not suitable for coronary intervention (Coronary artery bypass grafting or angioplasty) - so that best routine care is not withheld

• Do not have overt diabetes - work on this is being undertaken elsewhere

• Body mass index (BMI) greater than 25

Exclusion Criteria:

• Diabetes mellitus - see above

• Liver failure (ALT>70U/l, AST>80U/l)

• Renal failure (creatinine > 130mmol/l)

• Cardiac failure - rosiglitazone is contraindicated in those with NYHA 3 and 4 cardiac failure

• Physical disability - if it precludes treadmill testing

• Women of child bearing capacity

• Breast feeding mothers